IntraBio is a biopharmaceutical company focused on developing treatments for progressive neurological conditions. This page provides updates on their Levacetylleucine programme.   Levacetylleucine is a chemically modified version of the amino acid L-leucine. Amino acids […]
IntraBio and Levacetylleucine (AQNEURSA) updates Read More »
The pharmaceutical company Intrabio, who developed the recently FDA-approved drug AQNEURSA for people with Niemann-Pick Disease Type C, has announced their plans to begin a phase III trial of the
Intrabio to conduct phase III trial in SCA6 and Episodic Ataxia Type-2 Read More »
Dr. Alanna Watt is an Associate Professor in the department of biology at McGill University, Canada, and has been running the Watt Lab since 2011. The Watt Lab focuses on
Research by Prof Anja Lowit and her team at Strathclyde University, Glasgow, studying the effectiveness of a new type of speech therapy for some progressive ataxias, has shown some promising
